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BACKGROUND/PURPOSE: In Enterobacter cloacae and Serratia marcescens, AmpC β-lactamases can 
confer resistance to the third-generation cephalosporins and oxacephems, but not to the fourth-generation 
cephalosporins. Extended-spectrum β-lactamases (ESBL) may confer resistance to all extended-spectrum 
cephalosporins but not flomoxef. As difficult to detect, the ESBL phenotype of the intrinsically AmpC-
producing E. cloacae and S. marcescens is not routinely screened in the clinical microbiology laboratories. 
The distinct antibiotic resistance phenotype between ESBL- and AmpC-producers may assist to differenti-
ate the type of secreted β-lactamases. Therefore, we attested the validity of an antibiogram-based method 
to predict the presence of ESBLs in both species.
METHODS: Polymerase chain reaction-based methods and antibiogram-based methods were compared for 
their detection of ESBL in 74 E. cloacae and 69 S. marcescens isolates recovered from patients hospitalized at 
two medical centers in Taiwan. Three major types of antibiogram were defined: type I (3s4s), susceptible 
to cefotaxime, ceftazidime, and cefepime; type II (3r4s), resistant to cefotaxime or ceftazidime, but suscepti-
ble to cefepime; and type III (3r4r), resistant to cefepime plus cefotaxime and/or ceftazidime. Furthermore, 
subtype-a and subtype-b were defined as being resistant and susceptible to flomoxef, respectively.
RESULTS: Overall, ESBL producers were identified in 20 (27.0%) of Enterobacter and 11 (15.9%) of Serratia 
isolates by polymerase chain reaction-based methods. All type I isolates of both species (n = 49) were non-ESBL 
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Introduction
Plasmid-mediated extended-spectrum β-lactamases (ESBL), 
derived mainly from Temoniera (TEM)-type and sulfhy-
dryl variable (SHV)-type β-lactamases, are able to confer 
resistance to all extended-spectrum oxyiminocepha-
losporins (e.g. cefotaxime, ceftazidime, and cefepime), and 
monobactams (e.g. aztreonam).1 ESBLs do not hydrolyze 
7-α-methoxy β-lactams, including cephamycins (e.g. 
cefoxitin and cefotetan) or oxacephems (e.g. moxalactam 
and flomoxef).2
Since the first report of Klebsiella pneumoniae express-
ing an ESBL was published in 1983,3 the frequency of 
ESBL-producing Enterobacteriaceae has increased, and 
encompasses Escherichia coli and other organisms with 
chromosomal Bush group 1 (AmpC) β-lactamase, such 
as Enterobacter spp., Citrobacter spp., and Serratia spp.4–9 
Production of small amounts of inducible AmpC β-lacta-
mases causes intrinsic resistance of the AmpC producers to 
ampicillin and first-generation cephalosporins. Antibiotic 
induction of high AmpC β-lactamase leads to expression 
or selection of derepressed mutants, which produce high 
levels of the AmpC β-lactamase,10–12 has conferred resis-
tance to 7-α-methoxy β-lactams and to all cephalosporins 
except the fourth-generation agents (e.g. cefepime and 
cefpirome).2 The distinct antibiotic resistance phenotypes 
(antibiogram) between ESBL- and AmpC-producers may 
assist to differentiate the type of secreted β-lactamase.
Gene or protein sequencing is used for accurate identi-
fication of the Enterobacteriaceae β-lactamases. ESBL pro-
duction can be screened by both cefotaxime and 
ceftazidime, alone and in combination with clavulanate 
using phenotypic disks.13–15 The Clinical and Laboratory 
Standards Institute has issued recommendations for 
ESBL screening and confirmation for isolates of E. coli, 
K. pneumoniae, K. oxytoca, and Proteus mirabilis, but not for 
AmpC-producing organisms.16,17 Although phenotypic 
disk methods can be applied to AmpC producers, the 
major concern is that high-level expression of AmpC may 
prevent recognition of an ESBL in an AmpC-inducible 
species.7
ESBL-producing isolates of Enterobacter cloacae and 
Serratia marcescens have been identified in several hospitals 
in Taiwan.18–25 However, most clinical microbiology labo-
ratories do not currently screen for ESBL in E. cloacae and 
S. marcescens on a routine basis. Therefore, clinical physi-
cians need alternative ways to recognize these ESBL-
producing bacteria, such as an antibiogram-based method. 
Accordingly, the present study assesses the reliability of 
the antibiogram-based method using a panel containing 
cefotaxime, ceftazidime, cefepime, and flomoxef to pre-
dict the presence or absence of ESBLs in a consecutive col-
lection of clinical isolates of E. cloacae and S. marcescens. 
We initially hypothesized that ESBLs occurred in isolates 
with an antibiogram of resistance to ceftazidime, cefotax-
ime, and/or cefepime but susceptibility to flomoxef; 
whereas isolates with resistance to ceftazidime, cefotax-
ime and flomoxef, but susceptibility to cefepime, implied 
a predominant expression of AmpC β-lactamase.
Methods
Bacterial strains
Non-repetitive E. cloacae clinical isolates (n = 74) were ob-
tained from patients hospitalized at a university affiliated 
medical center in Central Taiwan from January 1 to June 30, 
producers. In E. cloacae, all subtype IIb (n = 6) and type III (n = 6) isolates produced ESBLs, but only 
8 of 17 IIa isolates produced ESBLs. The IIb and III types had the highest positive predictive value (100%) 
and specificity (100%) for ESBL detection. In S. marcescens, type II isolates rarely produced ESBLs (4/57 
isolates), while seven of type III (n = 8) isolates produced ESBLs. Type III antibiogram had the highest 
positive predictive value (87.5%) and specificity (98.3%) for ESBL detection.
CONCLUSION: The antibiograms of subtype IIb and type III are highly predictive for ESBL detection in 
E. cloacae, while type III is highly predictive for ESBL detection in S. marcescens. It is imperative to further 
examine ESBLs, focusing on the E. cloacae isolates with antibiogram subtype IIa.
KEYWORDS: antibiogram, Enterobacter cloacae, extended spectrum β-lactamases, resistance, 
Serratia marcescens
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2002. Non-repetitive S. marcescens bloodstream isolates 
(n = 69) were recovered from a 1,300-bed medical center in 
Southern Taiwan from August 1999 to July 2003. The iso-
lates were identified on the basis of routine microbiologic 
methods and species identification was confirmed using 
the VITEK system (BioMerieux Vitek Inc, Hazelwood, 
MD, USA).
Antibiogram
Antimicrobial susceptibility testing was performed using 
the disk diffusion method.16 The antibiogram in this 
study included the susceptibility profiles of cefepime 
(30 μg), cefotaxime (30 μg), ceftazidime (30 μg), and flo-
moxef (30 μg). The breakpoints for susceptible and resist-
ant categories of flomoxef were > 18 mm and < 12 mm 
respectively, according to the manufacturer’s instructions 
(BD Biosciences, USA). E. coli ATCC 25922 and Pseudomonas 
aeruginosa ATCC 27853 were used as control strains.
Confirmation test of ESBL phenotype
The combination-disk synergistic test (CDST) using cefo-
taxime, ceftazidime, and cefepime plus clavulanate (10 μg) 
was performed to detect ESBL production for all isolates. 
An ESBL phenotype was confirmed by a ≥ 5 mm increase 
in zone diameter for cefotaxime, ceftazidime or cefepime 
in combination with clavulanate versus its zone when 
tested alone. The combination disks included cefotaxime/
clavulanate and ceftazidime/clavulanate (BBL Sensi-
Disc, Becton Dickinson, Cockeysville, MD, USA) and 
cefepime/clavulanate (Neo-Sensitabs, Rosco Diagnostica, 
Taastrup, Denmark). The minimum inhibitory concen-
tration (MIC) of antimicrobial agents were determined by 
the agar dilution method.17 The ESBL phenotype was 
confirmed by a reduction of ≥ 3 log2 dilutions for the MIC 
of cefotaxime, ceftazidime or cefepime in the presence 
of clavulanic acid (4 μg/mL). Control experiments were 
assured by testing E. coli ATCC 25922 and K. pneumoniae 
700603.
Detection of blaSHV, blaTEM, blaCTX-M and 
AmpC genes
Polymerase chain reaction (PCR) was used to amplify the 
entire sequences of the blaSHV-12, blaCTX-M-3 and blaCTX-M-14, as 
well as the partial sequences of blaTEM.22,24,26 Specific primers 
were used to AmpC gene and blaSRT gene in the genomes of 
E. cloacae and S. marcescens isolates, respectively.24,27 Primer 
sequences were listed in Table 1. Amplicons were purified 
with PCR clean up kits (Roche Diagnostics, GmbH, 
Penzberg, Germany) and sequenced on an ABI PRISM 
3730 sequencer analyzer (Applied Biosystems, Foster City, 
CA, USA). Sequence analyses were performed online at the 
National Center for Biotechnology Information website.28
Statistical analysis
The PCR-based method was used as the standard detec-
tion method with the accuracy of ESBL detection results 
by other methods evaluated by sensitivity, specificity, pos-
itive predictive value, and negative predictive value.
Table 1. Primer sequences used in this study
Gene Primer Sequences Reference
blaSHV-12 forward 5-ATG CGT TAT ATT CGC CTG TG-3 22,24,26
 reverse 5-TTA GCG TTG CCA GTG CTC G-3 
blaCTX-M-3 forward 5-GGA TCC ATG GTT AAA AAA TCA CTG CG-3 
 reverse 5-AAG CTT TTA CAA ACC GTC GGT GAC-3 
blaCTX-M-14  forward 5-AAA AAT GAT TGA AAG GTG GTT GT-3 
 reverse 5-TTA CAG CCC TTC GGC GAT GA-3 
blaTEM  forward 5-ATA AAA TTC TTG AAG ACG AAA-3 
 reverse 5-GAC AGT TAC CAA TGC TTA ATC-3 
AmpC  forward 5-TCG GAA TTC CGG AGG ATT ACT GAT GAT GA-3 27
 reverse 5-TTA GTC GAC AAT GTT TTA CTG TAG CGC CTC G-3 
blaSRT  forward 5-GCC GAT ACC CTG CAA CCT AAG-3 24
 reverse 5-CGC CTG GAC GAT GTG GTA AG-3 
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Results
Bacterial strains, sources, and ESBL survey
Among the 74 non-repetitive E. cloacae isolates, 32 (43.2%) 
recovered from wound pus, 21 (28.4%) from urine, six 
(8.1%) from blood, six (8.1%) from central venous catheter 
tip, three (4.1%) from ascites, two (2.7%) from sputum, and 
four (5.4%) from other sources (Table 2). The CDST or the 
MIC-based methods were able to detect 16 ESBL producers 
(Table 3). The 74 isolates were surveyed for ESBL genes 
using PCR, which detected 4 additional ESBL producers 
(strains E11, E24, E34, and E35). Therefore, the sensitivity, 
specificity, positive predictive value, and negative predictive 
value of the CDST or the MIC-based method for ESBL 
detection in E. cloacae was 80.0%, 100%, 100%, and 93.1%, 
respectively. Twenty (27.0%) isolates carried alleles for the 
blaSHV-12 gene (Table 4). Subsequent DNA sequencing of all 
PCR products confirmed 100% homology to the blaSHV-12 
gene. The E95 and E96 isolates also contained blaCTX-M-14 
and blaCTX-M-3, respectively. TEM-1 β-lactamase was con-
firmed in 10 non-ESBL isolates. The ESBL producers were 
most commonly isolated from central venous catheter-tip, 
urine, ascites, and pus specimens (Table 2).
From 69 bacteremic isolates of S. marcescens, the CDST 
or MIC-based methods were able to detect nine ESBL pro-
ducers (Table 5) while a total of 11 ESBL producers were 
identified by PCR, including 10 isolates producing CTX-
M-3 and one producing SHV-12 (Table 6). The sensitivity, 
Table 3. Antibiogram and positive ESBL tests of 74 Enterobacter cloacae isolates
 Antibiogram Positive ESBL tests by Predictive values of various antibiogram
    CDST or PCR-based 
PPV
 
NPV
 
Sensitivity
 
Specificity
Type CAZ/CTX FFP FLO MIC-based methods    
    methods (n = 16) (n = 20) 
(%)
 
(%)
 
(%)
 
(%)
Ia Sa S R 0/9 0/9 0 31.0 – –
Ib Sa S S 0/36 0/36    
IIa Rb S R 4/17 8c/17 47.1 78.9 – –
IIb Rb S S 6/6 6/6 100 87.1 60.0 100
IIIa Rb R R 5/5 5/5    
IIIb Rb R S 1/1 1/1    
Sensitivity (%)  –  80.0 Standard   –
Specificity (%)  –  100 Standard   –
PPV (%)  –  100 Standard   –
NPV (%)  –  93.1 Standard   –
aSusceptible to both CAZ and CTX; bresistant to either CAZ and/or CTX; cfour isolates (E11, E24, E34, and E35) containing blaSHV-12 gave a 
false negative result when phenotypic disk and MIC-based extended-spectrum β-lactamases detection methods were employed (see Table 5). 
ESBL = extended-spectrum β-lactamases; CAZ = ceftazidime; CTX = cefotaxime; FEP = cefepime; FLO = flomoxef; CDST = combination-disk 
synergistic test; MIC = minimum inhibitory concentration; PCR = polymerase chain reaction ; PPV = positive predictive value; NPV = negative 
predictive value; S = susceptible; R = resistant.
Table 2. Sources and extended-spectrum β-lactamases 
prevalances among the non-repetitive Enterobacter cloacae 
isolatesa
Specimen No of isolates ESBL Prevalencec
Pus 32 (43.2) 6 (18.8)
Urine 21 (28.4) 9 (42.9)
Blood 6 (8.1) 0 (0)
Central venous 6 (8.1) 4 (66.7)
 catheter tip
Ascites  3 (4.1) 1 (33.3)
Sputum 2 (2.7) 0 (0)
Othersb 4 (5.4) 0 (0)
Total 74 (100) 20 (27.0)
aData presented as n (%); bone each for bile, pleural fluid, cerebrospinal 
fluid and bronchoalveolar lavage; camong the positive isolates from 
each specimen group.
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specificity, positive predictive value, and negative predic-
tive value of the CDST or MIC-based methods for ESBL 
detection in S. marcescens were 81.8%, 100%, 100%, and 
96.7%, respectively (Table 5).
Antibiogram
Antibiograms of the 74 E. cloacae isolates revealed suscep-
tibility profiles to cefotaxime, ceftazidime, and cefepime, 
and were classified into three major types (Types I–III). 
Each type could be further classified into subtype-a (resis-
tant to flomoxef) or subtype-b (susceptible to flomoxef) 
(Table 3). Type I (3s4s) isolates (n = 45) were susceptible to 
cefotaxime, ceftazidime, and cefepime, and were all non-
ESBL producers. All ESBL producers were distributed 
among the type II (3r4s) and III (3r4r) E. cloacae isolates. 
The occurrence of ESBL among subtype IIa (3r4sFr) 
isolates was 47.1% (8/17). However, four ESBL producers 
were not detected by phenotypic ESBL methods. The 
subtype IIb (3r4sFs) and type III (3r4r) isolates were 
confirmed as ESBL producers. Overall, the prevalence of 
ESBL in E. cloacae isolates with various antibiograms 
were type Ia, 0%; Ib, 0%; IIa, 47.1% (8/17 isolates); IIb, 100% 
(6/6 isolates); IIIa, 100% (5/5 isolates); and IIIb, 100% 
(1/1 isolates) (Table 3). The sensitivity, specificity, positive 
predictive value, and negative predictive value of the anti-
biograms including subtype IIb and type III for ESBL 
detection in E. cloacae was 60.0%, 100%, 100%, and 87.1%, 
respectively.
Similarly, the prevalence of ESBL for 69 S. marcescens 
isolates with various antibiograms were type I, 0%; IIa, 0%; 
IIb, 8.9% (4/45 isolates); IIIa, 66.7% (2/3 isolates); and 
IIIb, 100% (5/5 isolates) (Table 5). Only two ESBL-
producing S. marcescens isolates (strains no. 109 and 122) 
were not detected by phenotypic methods (Table 6). The 
sensitivity, specificity, positive predictive value, and nega-
tive predictive values of the type III antibiogram ESBL 
Table 4. Minimum inhibitory concentrations, antibiogram, and genotypes of 20 strains of ESBL-producing Enterobacter cloacae
Strains
 MIC (μg/mL) 
Antibiogram
 ESBL
 CTX CTX/CLA CAZ CAZ/CLA FEP FEP/CLA  SHV CTX-M
E2 16 0.50 64 4 2 0.12 IIa SHV-12 –
E6 16 0.25 64 0.50 2 0.06 IIb SHV-12 –
E9 16 0.25 128 0.50 2 0.06 IIb SHV-12 –
E11a 64 128 128 64 2 1 IIa SHV-12 –
E13 128 4  > 512 16 32 0.25 IIIa SHV-12 –
E19 128 2  > 512 8 16 0.12 IIIa SHV-12 –
E24a 64 128 256 128 4 2 IIa SHV-12 –
E25 16 1 32 0.50 1 0.12 IIa SHV-12 –
E34a 32 128 64 64 2 0.50 IIa SHV-12 –
E35a 16 16 32 32 0.50 0.12 IIa SHV-12 –
E43 8 0.25 64 1 1 0.12 IIIa SHV-12 –
E47 8 0.50 128 8 2 0.06 IIa SHV-12 –
E68 16 0.50 128 1 2 0.06 IIb SHV-12 –
E71 64 1 512 4 16 0.12 IIIa SHV-12 –
E73 32 0.50 128 1 4 0.06 IIb SHV-12 –
E75 32 0.25 256 1 4 0.06 IIb SHV-12 –
E89 32 1 64 32 2 0.25 IIa SHV-12 –
E95 128 0.50 8 0.50 32 0.12 IIIb SHV-12 CTX-M-14
E96 512 16 16 32 32 0.25 IIIa SHV-12 CTX-M-3
E98 128 64 512 32 32 1 IIIa SHV-12 –
afalse negative ESBL result by phenotypic methods. MIC = minimum inhibitory concentration; ESBL = extended-spectrum β-lactamases; 
CTX = cefotaxime; CLA = clavulanic acid; CAZ = ceftazidime; FEP = cefepime; SHV = sulfhydryl variable.
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detection in S. marcescens were 63.6%, 98.3%, 87.5%, and 
93.4%, respectively.
Survey for chromosomal AmpC gene
The alleles of AmpC gene in the 29 E. cloacae isolates 
with antibiogram types II and III were characterized by 
PCR. Each isolate produced a 1,165-bp PCR fragment 
containing the AmpC gene. Subsequent DNA sequencing 
of the PCR products from strains E71 and E11 revealed 
99% and 97% identity to bla(EcloK995120.1) and bla
(EcloK9973), respectively, which were the chromosomal 
AmpC gene of E. cloacae found in Korea.27 Furthermore, 
Table 5. The antibiogram and positive ESBL tests of 69 Serratia marcescens isolates
 Antibiogram Positive ESBL tests by Predictive values of various antibiogram
     CDST or PCR-based 
PPV
 
NPV
 
Sensitivity
 
Specificity
 Type CAZ/CTX FFP FLO MIC-based methods    
     methods (n = 9)  (n = 11) 
(%)
 
(%)
 
(%)
 
(%)
 Ia Sa S R 0/0 0/0    
 Ib Sa S S 0/4 0/4 0 79.2 – –
 IIa Rb S R 0/12 0/12    
 IIb Rb S S 2/45 4c/45  8.9 70.8 – –
 IIIa Rb R R 2/3 2/3    
 IIIb Rb R S 5/5 5/5 
87.5  9.4 63.6 98.3
 Sensitivity (%)  –  81.8 Standard   –
 Specificity (%)  –  100 Standard   –
 PPV (%)  –  100 Standard   –
 NPV (%)  –  96.7 Standard   –
aSusceptible to both CAZ and CTX; bresistant to either CAZ and/or CTX; ctwo isolates (strains no. 109 and 122) containing blaCTX-M-3 gave 
false negative results by phenotypic disk and MIC-based extended-spectrum β-lactamases detection methods (see Table 6). ESBL = extended-
spectrum β-lactamases; CAZ = ceftazidime; CTX = cefotaxime; FEP = cefepime; FLO = flomoxef; CDST = combination-disk synergistic test; 
MIC = minimum inhibitory concentration; PCR = polymerase chain reaction; PPC = positive predictive value; NPV = negative predictive value; 
S = susceptible; R = resistant.
Table 6. MICs, antibiogram, and genotypes of 11 strains of ESBL-producing serratia marcescens
Strains
 MIC (μg/mL)  ESBL
 CAZ CAZ/CLA CTX CTX/CLA FEP FEP/CLA 
Antibiogram
 CTX-M SHV
5 2 1 64 8 16 0.50 IIIb CTX-M-3 –
101 128 1 8 4 1 0.25 IIb – SHV-12
109a 0.50 0.50 16 8 0.25 0.25 IIb CTX-M-3 –
122a 0.50 0.50 16 8 0.25 0.25 IIb CTX-M-3 –
125 16 2  > 128 16  > 128 2 IIIa CTX-M-3 –
127 2 1  > 128 32 64 2 IIIb CTX-M-3 –
172 2 0.12 128 2 32 0.12 IIIb CTX-M-3 –
174 2 0.5 64 8 16 0.50 IIIb CTX-M-3 –
192 1 0.12 64 2 4 0.12 IIb CTX-M-3 –
199 4 0.12  > 128 0.50 64 0.06 IIIb CTX-M-3 –
200 2 1  > 128 32 64 2 IIIa CTX-M-3 –
afalse negative ESBL test results by phenotypic methods. MIC = minimum inhibitory concentration; ESBL = extended-spectrum β-lactamases; 
CAZ = ceftazidime; CLA = clavulanic acid; CTX = cefotaxime; FEP = cefepime; SHV = sulfhydryl variable.
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these AmpC-like genes were detected in type Ia (6/9) and 
type Ib (7/36) E. cloacae isolates.
With respect to S. marcescens, only strain no. 125 did 
not harbor a chromosomal SRT-like AmpC enzyme. The 
remaining 58 non-ESBL producers were confirmed as 
positive AmpC producers by PCR.
MIC determination
Detailed MIC values and ESBL genotypes of the ESBL-
producing E. cloacae isolates (n = 20) and S. marcescens iso-
lates (n = 11) can be found in Tables 4 and 6, respectively. 
The MICs of cefotaxime, ceftazidime, and cefepime for the 
20 Enterobacter ESBL producers ranged from 8 to 512 μg/
mL, 8 to > 512 μg/mL, and 0.5 to 32 μg/mL, respectively. 
Of the 20 Enterobacter ESBL producers, 70.0% (14/20) were 
susceptible to cefepime (MIC < 8 μg/mL). A significant 
reduction of MICs for cefotaxime, ceftazidime, and 
cefepime in the presence of clavulanate was not achieved 
for four Enterobacter ESBL producers (strains E11, E24, 
E34, and E35) and two Serratia ESBL producers (strains 
no. 109 and 122).
Discussion
This analysis determined that the antibiogram-based 
method might be used as an initial screening method for 
ESBL detection in E. cloacae and S. marcescens. The antibio-
grams of subtype IIb and type III are highly predictive of 
ESBL detection in E. cloacae, whilst the antibiogram of type 
III is highly predictive of ESBL detection in S. marcescens. 
The type I antibiogram is highly predictive of non-ESBL 
producers for both species.
Many studies have reported a diverse prevalence of 
resistant strains of Enterobacter spp. and S. marcescens that 
produce plasmid-mediated ESBLs.4,5,7–9,18–25,29,30 The 
increasing reports of ESBL-producing Enterobacter and 
Serratia isolates in Taiwan emphasizes the need for a bet-
ter understanding of ESBL production in clinical isolates. 
However, ESBL detection can be challenging, because the 
inhibitor-based method can be confounded by the high 
level production of AmpC enzymes which are resistant to 
clavulanate. Some investigators suggested that an elevated 
MIC of cefepime > 0.25 μg/mL,8 or ≥ 1 μg/mL,9 has the 
highest sensitivity (100% and 95.3%, respectively) and 
specificity (74% and 82.7%, respectively) for the presence 
of an ESBL. Similarly, no non-ESBL producing E. cloacae 
strains had MICs of cefepime ≥ 2 μg/mL.31 However, most 
clinical microbiology laboratories perform the disk diffu-
sion method to measure antibiotic susceptibility on a rou-
tine basis and do not use MIC-based techniques in Taiwan. 
Thus the disk antibiogram-based method may be an 
acceptable strategy for ESBL screening.
Isolates of Enterobacter and Serratia with concurrent 
susceptibilities to cefotaxime, ceftazidime, and cefepime 
(type I antibiogram), implying minimal or no induction 
of the chromosomal AmpC enzymes, have a low likeli-
hood of ESBL production. Similar to our results, were 
those from a report in Korea stating the susceptibility of 
the ESBL producers E. cloacae, C. freundii, and S. marcescens 
to ceftazidime, cefotaxime, and aztreonam (MICs < 8 μg/
mL each) was very low (0.04–0.27%).9 These facts suggest 
that these ESBL-producing organisms rarely maintain 
simultaneous susceptibility to all extended-spectrum cepha-
losporins. Thus it seems unnecessary to perform an ESBL 
test for isolates with a type I antibiogram, because the 
likelihood of a false negative result that might lead to 
inadequate treatment is negligible.
The mechanisms conferring resistance to the cepha-
losporins tested in our study are multifactorial. Isolates of 
subtype Ia with resistance to flomoxef likely exhibited an 
outer membrane protein defect.32 The isolates of subtype 
IIa with resistance to flomoxef plus ceftazidime and/or 
cefotaxime but susceptibility to cefepime had a character-
istic AmpC phenotype, confirmed by the AmpC PCR. 
Nevertheless, 47% of subtype IIa Enterobacter isolates were 
ESBL producers. These findings differ from our initial 
hypothesis in which antibiogram pattern would be used 
to predict AmpC producers. Four of the eight subtype IIa 
ESBL producers exhibited a positive ESBL phenotype, 
implying a greater activity of ESBL than that of AmpC 
β-lactamase.1,2 These data refute the interpretation of all 
subtype IIa E. cloacae isolates as non-ESBL producers and 
support mandatory testing for ESBL production.
The subtype IIb or IIIb isolates which exhibit resis-
tance to ceftazidime, cefotaxime and/or cefepime but 
susceptibility to flomoxef are characteristic of ESBL 
producers.1,2 However, subtype IIb significantly correlated 
with ESBL production in E. cloacae but not S. marcescens 
isolates, as ESBLs occurred in only 8.9% of subtype IIb 
S. marcescens. The antibiogram-based method correctly 
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predicted ESBL production in isolates with cefepime 
resis tance (type III) regardless of flomoxef susceptibility. 
Once again, these findings contrast from our initial 
hypothesis of using an antibiogram pattern to predict 
ESBL producers. A cost–benefit evaluation of antibio-
grams for the detection of ESBL-producing subtype IIb 
S. marcescens may be warranted in hospitals. We suggest 
that there is no need to test for ESBL from S. marcescens 
with a subtype IIb antibiogram. In summary, these results 
indicated that only type III S. marcescens and type IIb and 
III E. cloacae should be regarded as ESBL producers.
The mortality of patients from E. cloacae bacteremia is 
significantly higher in ESBL carriers with most harboring 
SHV-12 when compared with non-ESBL carriers.19 Addi-
tionally, reduced susceptibility to cefepime among ESBL 
producers in the members of Enterobacteriaceae has become 
a major reason for potential therapeutic failure.29,31,33 The 
possibly high rates of susceptibility to cefepime by ESBL 
producers re-emphasizes the importance for clinical 
physicians to be able to recognize ESBL production in 
E. cloacae and S. marcescens. With the aid of the antibio-
gram-based ESBL screening method described in our 
study, targeting effective antimicrobials to patients har-
boring ESBL producers is possible. Since these specimens 
were isolated only from Taiwan, its applicability to other 
geographical populations warrants further study.
In conclusion, despite that the Clinical and Laboratory 
Standards Institute methods are not issued for the detec-
tion of E. cloacae and S. marcescens EBSL, we suggest a sim-
ple and reliable method for physicians to detect ESBL 
production among these AmpC producers. For S. marces-
cens, ESBLs commonly occurred in isolates with a type III 
antibiogram; in E. cloacae, ESBLs frequently occurred in 
isolates with type III or subtype IIb antibiogram. However, 
ESBLs also occurred in some of the subtype IIa strains. 
Therefore, further ESBL testing should be focused on the 
subtype IIa Enterobacter isolates. Our antibiogram-based 
method may simplify the screening of potential ESBL-
producing populations among AmpC-producing organisms.
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